Apr 10 |
Altamira Therapeutics GAAP EPS of -CHF14.80
|
Apr 10 |
Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
|
Apr 10 |
Earnings Scheduled For April 10, 2024
|
Apr 4 |
Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
|
Mar 25 |
Altamira stock rallies 44% on Univercells mRNA collaboration
|
Mar 25 |
Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines
|
Feb 7 |
Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
|
Jan 24 |
Altamira Therapeutics stock jumps 7% as it files for second patent
|
Jan 24 |
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
|
Jan 8 |
Altamira Therapeutics files to sell 162.5K shares
|